Boundless Bio Inc. (BOLD)

Boundless Bio's stock (BOLD) has experienced significant volatility, with a 56.04% decline from January 2, 2025, to December 31, 2025, after its IPO in March 2024. In May 2025, preliminary data from the Phase 1/2 trial of BBI-355 revealed hematological toxicity, leading to a halt in its development as a single agent and a pivot to combination testing. Also in May 2025, the company laid off approximately one-third of its staff to extend its cash runway into the first half of 2028. In August 2025, the company reported a 17% drop in Q2 R&D. In November 2025, Boundless Bio reported its Third Quarter 2025 Financial Results and Business Highlights. In December 2025, the company's price target was decreased by 14.29% to $3.06. The company has a consensus rating of "Hold" from analysts, with an average price target of $3.50.

The demand for Boundless Bio's products and services is not subject to typical seasonal fluctuations, as it is primarily driven by the prevalence of oncogene-amplified cancers, the progression of its clinical pipeline, and the success of its therapeutic candidates.

Boundless Bio, Inc. is a clinical-stage oncology company focused on developing novel cancer therapeutics by targeting extrachromosomal DNA (ecDNA). The company operates within the Healthcare sector, specifically in the Biotechnology and Drug Discovery industries, with the core mission to address the unmet needs of patients with oncogene-amplified tumors. Its major product candidates include BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 clinical trials; BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1; BBI-825, a novel, oral, selective inhibitor of ribonucleotide reductase (RNR), which was halted as a monotherapy due to toxicity issues; ECHO, an ecDNA diagnostic test; and the Spyglass platform, used to identify druggable targets and develop ecDNA-directed therapies.

Boundless Bio, Inc. is headquartered in San Diego, California, United States.

Boundless Bio's brand reputation has likely been negatively impacted by challenges in its clinical trials, including the narrow therapeutic window of BBI-355 and the subsequent layoff of one-third of its staff. Despite these setbacks, the company continues to present research at conferences, and analyst ratings include "Buy" recommendations, suggesting continued confidence in its long-term potential.

Boundless Bio, Inc. has a mixed ownership structure, with institutional investors owning approximately 25.75% to 28.59% of the stock, insiders owning 8.20% to 23.82%, and public companies and individual investors owning up to 63.21%. Major institutional owners include Fmr Llc, Nextech Invest, Ltd., Fidelity Growth Company Fund (FDGRX), Citadel Advisors Llc, Sectoral Asset Management Inc, Vanguard Group Inc, Wellington Management Group Llp, Stonepine Capital Management, LLC, Alyeska Investment Group, L.P., Arch Venture Partners, L.P., RA Capital Management, L.P., and BlackRock, Inc. Key individual owners and insiders include Kristina Burow, Keith Crandell, Jonathan E. Lim, and Peter Kolchinsky.